Method for treating cancer with a nanoformulation

Patent metadata

Field	Value
Publication number	US-11723920-B2
Application number	US-202117530002-A
Country	US
Kind code	B2
Filing date	Nov 18, 2021
Priority date	Apr 25, 2019
Publication date	Aug 15, 2023
Grant date	Aug 15, 2023

Abstract

A nanotherapeutic having platinum complexes encapsulated by a nanoformulation containing at least one spinel ferrite of formula CuFe2O4, NiFe2O4, CoFe2O4, and MnFe2O4 deposited on mesoporous silica. A method of preparing the nanotherapeutic that involves mixing a metal(II) salt and a Fe(III) salt with the mesoporous silica nanoparticles to form a powdery mixture, calcining the powdery mixture to form the nanoformulation, and mixing the nanoformulation with the platinum complex. A method for treating cancer with the nanotherapeutic.

First claim

The invention claimed is:

1. A method for treating a proliferative disorder, the method comprising administering a nanotherapeutic to a subject in need of therapy,
wherein the nanotherapeutic comprises:
a nanoformulation comprising:
mesoporous silica nanoparticles in the form of monodispersed spherical silica having a particle size distribution of about 80 nm; and
spinel ferrite nanoclusters of formula (I)
MFe 2 O 4   (I)

wherein M is at least one transition metal element selected from the group consisting of Cu and Ni;
wherein:
the spinel ferrite nanoclusters are impregnated on the mesoporous silica nanoparticles; and
the spinel ferrite nanoclusters are present in an amount of 25-35 wt % relative to a total weight of the nanoformulation, and

cisplatin encapsulated within pores of the nanoformulation,
wherein the nanoformulation has a cisplatin release at a pH 5 at 37° C. for 72 h of 60-80 wt. %;
wherein the pores of the nanoformulation have a pore diameter in a range of 10-25 nm, and the nanoformulation has a pore volume in a range of 0.05 0.3 cm 3 /g, a BET surface area in a range of 15-70 m 2 /g, and a saturation magnetization value in a range of 7-15 emu/g; and
wherein the proliferative disorder is a cancer selected from the group consisting of breast cancer, ovarian cancer, cervical cancer, testicular cancer, colon cancer, bladder cancer, and lung cancer.

2. The method of claim 1 , wherein the nanotherapeutic further comprises one or more pharmaceutically acceptable carriers and/or excipients selected from the group consisting of a buffer, an inorganic salt, a fatty acid, a vegetable oil, a synthetic fatty ester, a surfactant, and a polymer.

3. The method of claim 1 , wherein the cisplatin is present at a concentration of 0.01-10 mmol/g relative to a total weight of the nanoformulation.

4. The method of claim 1 , wherein 0.5-800 mg/kg of the nanotherapeutic is administered per body weight of the subject.

5. The method of claim 1 , wherein the cancer proliferative disorder is breast cancer.

6. The method of claim 1 , wherein the subject is a mammal.

Assignees

• Univ Imam Abdulrahman Bin Faisal

Inventors

• Jermy B Rabindran
• Ravinayagam Vijaya
• Baykal Abdulhadi

Classifications

• A61K33/243 Primary

  Platinum; Compounds thereof · CPC title

• A61K47/02

  Inorganic compounds · CPC title

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• A61K47/14

  Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters · CPC title

• B82Y5/00

  Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery · CPC title